Biotree

Based in Shanghai, China and established in 2012, Biotree is a biology technology company that engages in the R&D of metabolomics and proteomics. The company cooperated with over 1500 universities, R&D institutions, hospitals, and pharmaceutical enterprises. It has completed 3 rounds of funding as of 2023. The company provides testing and analysis services in life science, including R&D services, pharmaceutical enterprise services, clinical mass spectrometry services, and big data informatization service platform.

The company's genomics service can be used for disease early screening and diagnosis products. The company has multiple testing analysis platforms, including non-targeted metabolomics, high-throughput targeted metabolomics, lipidomics, metabolic flow, proteomics, and antibody sequencing. The company will use the Series A funding to expand R&D centers of omics, R&D and production of testing kits, and promote the clinic transformation process of mass spectrometry and genomics.